PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin

Journal of Controlled Release

Volumn 162, Issue 2, 2012, Pages 310-320

  Patel, Brijeshkumar ^a   Gupta, Vivek ^a   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Highly water soluble drugs; Low molecular weight heparin; Microparticles; PEG PLGA; Pulmonary delivery

Indexed keywords

LOW-MOLECULAR WEIGHT HEPARINS; MICRO-PARTICLES; PEG-PLGA; PULMONARY DELIVERY; WATER SOLUBLE DRUGS;

BLOCK COPOLYMERS; CYTOTOXICITY; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; POLYMERS; POLYSACCHARIDES; POROUS MATERIALS; SODIUM CHLORIDE;

POLYETHYLENE OXIDES;

LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; POLYGLACTIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; IN VIVO STUDY; LUNG; LUNG ALVEOLUS; LUNG LAVAGE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ADMINISTRATION, INHALATION; ALKALINE PHOSPHATASE; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; DRUG CARRIERS; HEPARIN, LOW-MOLECULAR-WEIGHT; L-LACTATE DEHYDROGENASE; LUNG; MACROPHAGES, ALVEOLAR; MALE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; POROSITY; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84865340746     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.07.003     Document Type: Article

References (51)

1. J.A. Straub, D.E. Chickering, J.C. Lovely, H. Zhang, B. Shah, W.R. Waud, and H. Bernstein Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850) Pharm. Res. 22 2005 347 355
2. L. Javot, T. Lecompte, M. Rabiskova, and P. Maincent Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio J. Control. Release 139 2009 8 14
3. Y.J. Oh, J. Lee, J.Y. Seo, T. Rhim, S.H. Kim, H.J. Yoon, and K.Y. Lee Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model J. Control. Release 150 2011 56 62
4. V. Gupta, M. Davis, L.J. Hope-Weeks, and F. Ahsan PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-beta-cyclodextrin (PGE1-HPbetaCD) complex for the treatment of pulmonary arterial hypertension (PAH) Pharm. Res. 28 2011 1733 1749
5. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer Large porous particles for pulmonary drug delivery Science 276 1997 1868 1871
6. N.Y. Yoo, Y.S. Youn, N.M. Oh, K.T. Oh, D.K. Lee, K.H. Cha, Y.T. Oh, and E.S. Lee Antioxidant encapsulated porous poly(lactide-co-glycolide) microparticles for developing long acting inhalation system Colloids Surf. B 88 2011 419 424
7. S.S. Feng, L. Mu, K.Y. Win, and G.F. Huang Nanoparticles of biodegradable polymers for clinical administration of paclitaxel Curr. Med. Chem. 11 2004 413 424
8. L. Mu, and S.S. Feng Fabrication, characterization and in vitro release of paclitaxel (Taxol (R)) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers J. Control. Release 76 2001 239 254
9. C.W. Chang, D. Choi, W.J. Kim, J.W. Yockman, L.V. Christensen, Y.H. Kim, and S.W. Kim Non-ionic amphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle J. Control. Release 118 2007 245 253
10. J. Guo, X. Gao, L. Su, H. Xia, G. Gu, Z. Pang, X. Jiang, L. Yao, J. Chen, and H. Chen Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery Biomaterials 32 2011 8010 8020
11. M.E. Norman, P. Williams, and L. Illum Influence of block copolymers on the adsorption of plasma proteins to microspheres Biomaterials 14 1993 193 202
12. M. Luck, K.F. Pistel, Y.X. Li, T. Blunk, R.H. Muller, and T. Kissel Plasma protein adsorption on biodegradable microspheres consisting of poly(D, L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition J. Control. Release 55 1998 107 120
13. K. Avgoustakis Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery Curr. Drug Deliv. 1 2004 321 333
14. F. Danhier, N. Lecouturier, B. Vroman, C. Jerome, J. Marchand-Brynaert, O. Feron, and V. Preat Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation J. Control. Release 133 2009 11 17
15. S. Moffatt, and R.J. Cristiano PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells Int. J. Pharm. 317 2006 10 13
16. R. Paliwal, S.R. Paliwal, G.P. Agrawal, and S.P. Vyas Recent advances in search of oral heparin therapeutics Med. Res. Rev. 32 2012 388 409
17. S. Bai, C. Thomas, and F. Ahsan Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin J. Pharm. Sci. 96 2007 2090 2106
18. T. Yang, F. Mustafa, S. Bai, and F. Ahsan Pulmonary delivery of low molecular weight heparins Pharm. Res. 21 2004 2009 2016
19. Y.Y. Jiao, N. Ubrich, M. Marchand-Arvier, C. Vigneron, M. Hoffman, and P. Maincent Preparation and in vitro evaluation of heparin-loaded polymeric nanoparticles Drug Deliv. 8 2001 135 141
20. S.S. Oliveira, F.S. Oliveira, C.M. Gaitani, and J.M. Marchetti Microparticles as a strategy for low-molecular-weight heparin delivery J. Pharm. Sci. 100 2011 1783 1792
21. A. Rawat, Q.H. Majumder, and F. Ahsan Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation J. Control. Release 128 2008 224 232
22. J.M. Pean, M.C. Venier-Julienne, F. Boury, P. Menei, B. Denizot, and J.P. Benoit NGF release from poly(D, L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability J. Control. Release 56 1998 175 187
23. J.L. Chen, C.H. Chiang, and M.K. Yeh The mechanism of PLA microparticle formation by water-in-oil-in-water solvent evaporation method J. Microencapsul. 19 2002 333 346
24. J.L. Chen, M.K. Yeh, and C.H. Chiang The mechanism of surface-indented protein-loaded PLGA microparticle formation: the effects of salt (NaCl) on the solidification process J. Microencapsul. 21 2004 877 888
25. S. Jaraswekin, S. Prakongpan, and R. Bodmeier Effect of poly(lactide-co-glycolide) molecular weight on the release of dexamethasone sodium phosphate from microparticles J. Microencapsul. 24 2007 117 128
26. K.F. Pistel, and T. Kissel Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique J. Microencapsul. 17 2000 467 483
27. V.F. Patel, and N.M. Patel Statistical evaluation of influence of xanthan gum and guar gum blends on dipyridamole release from floating matrix tablets Drug Dev. Ind. Pharm. 33 2007 327 334
28. M.I. Amaro, L. Tajber, O.I. Corrigan, and A.M. Healy Optimisation of spray drying process conditions for sugar nanoporous microparticles (NPMPs) intended for inhalation Int. J. Pharm. 421 2011 99 109
29. R. Vanbever, J.D. Mintzes, J. Wang, J. Nice, D. Chen, R. Batycky, R. Langer, and D.A. Edwards Formulation and physical characterization of large porous particles for inhalation Pharm. Res. 16 1999 1735 1742
30. F. Ungaro, G. De Rosa, A. Miro, F. Quaglia, and M.I. La Rotonda Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs Eur. J. Pharm. Sci. 28 2006 423 432
31. V. Gupta, A. Rawat, and F. Ahsan Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension J. Pharm. Sci. 99 2010 1774 1789
32. M.D. Klein, R.A. Drongowski, R.J. Linhardt, and R.S. Langer A colorimetric assay for chemical heparin in plasma Anal. Biochem. 124 1982 59 64
33. O.R. Moss Simulants of lung interstitial fluid Heal. Phys. 36 1979 447 448
34. C. Thomas, V. Gupta, and F. Ahsan Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses Int. J. Pharm. 379 2009 41 50
35. D.A. Scudiero, R.H. Shoemaker, K.D. Paull, A. Monks, S. Tierney, T.H. Nofziger, M.J. Currens, D. Seniff, and M.R. Boyd Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines Cancer Res. 48 1988 4827 4833
36. C. Thomas, V. Gupta, and F. Ahsan Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles Pharm. Res. 27 2010 905 919
37. F. Ito, H. Honnami, H. Kawakami, K. Kanamura, and K. Makino Preparation and properties of PLGA microspheres containing hydrophilic drugs by the SPG (shirasu porous glass) membrane emulsification technique Colloids Surf. B: Biointerfaces 67 2008 20 25
38. I. Dimitrov, B. Trzebicka, A.H.E. Muller, A. Dworak, and C.B. Tsvetanov Thermosensitive water-soluble copolymers with doubly responsive reversibly interacting entities Prog. Polym. Sci. 32 2007 1275 1343
39. C. Tan, J.G. Albright, and O. Annunziata Determination of preferential interaction parameters by multicomponent diffusion. applications to poly(ethylene glycol)-salt-water ternary mixtures J. Phys. Chem. B 112 2008 4967 4974
40. X. Luan, M. Skupin, J. Siepmann, and R. Bodmeier Key parameters affecting the initial release (burst) and encapsulation efficiency of peptide-containing poly(lactide-co-glycolide) microparticles Int. J. Pharm. 324 2006 168 175
41. R. Gref, P. Quellec, A. Sanchez, P. Calvo, E. Dellacherie, and M.J. Alonso Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers Eur. J. Pharm. Biopharm. 51 2001 111 118
42. J. He, M. Feng, X. Zhou, S. Ma, Y. Jiang, Y. Wang, and H. Zhang Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer Int. J. Pharm. 416 2011 69 76
43. G. Jiang, B.C. Thanoo, and P.P. DeLuca Effect of osmotic pressure in the solvent extraction phase on BSA release profile from PLGA microspheres Pharm. Dev. Technol. 7 2002 391 399
44. B. Ronneberger, W.J. Kao, J.M. Anderson, and T. Kissel In vivo biocompatibility study of ABA triblock copolymers consisting of poly(L-lactic-co-glycolic acid) A blocks attached to central poly(oxyethylene) B blocks J. Biomed. Mater. Res. 30 1996 31 40
45. M. Korber PLGA erosion: solubility- or diffusion-controlled? Pharm. Res. 27 2010 2414 2420
46. S.D. Xiang, A. Scholzen, G. Minigo, C. David, V. Apostolopoulos, P.L. Mottram, and M. Plebanski Pathogen recognition and development of particulate vaccines: does size matter? Methods 40 2006 1 9
47. D.A. Edwards, A. Ben-Jebria, and R. Langer Recent advances in pulmonary drug delivery using large, porous inhaled particles J. Appl. Physiol. 85 1998 379 385
48. G. Fontana, M. Licciardi, S. Mansueto, D. Schillaci, and G. Giammona Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake Biomaterials 22 2001 2857 2865
49. A. Yang, L. Yang, W. Liu, Z. Li, H. Xu, and X. Yang Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation Int. J. Pharm. 331 2007 123 132
50. M. Geiser, and W.G. Kreyling Deposition and biokinetics of inhaled nanoparticles Part. Fibre Toxicol. 7 2010 2
51. P. Bianchini, G.L. Bergonzini, B. Parma, and B. Osima Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass Haemostasis 25 1995 288 298